AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34587373 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized BP-lowering treatment
Number of subjects: 242
Study 34587373 — intervention group
Group type: COMPARATOR
Intervention: Standard BP-lowering treatment
Number of subjects: 242
Study 33601858 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily for 5 days along with general supportive treatment
Number of subjects: 200
Study 33601858 — intervention group
Group type: COMPARATOR
Intervention: Standard supportive treatment
Number of subjects: 200
Study 34741703 — intervention group
Group type: EXPERIMENTAL
Intervention: SAAF substance use prevention program (7-session family skills training program)
Number of subjects: 252
Study 32524129 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic enteral and parenteral nutrition support with ω‐3 fish oil fat milk injection and glutamine
Number of subjects: 56
Study 32524129 — intervention group
Group type: COMPARATOR
Intervention: Routine postoperative enteral and parenteral camp support
Number of subjects: 56
Study 32524129 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic enteral and parenteral nutrition support
Number of subjects: 56
Study 33031491 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) using Evolut or Evolut PRO valve
Number of subjects: 150
Study 35584865 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (1.2 mg/kg), doxorubicin (25 mg/m2), vinblastine (6 mg/m2), dacarbazine (375 mg/m2), and rituximab (375 mg/m2) for four or six cycles.
Number of subjects: 30
Study 35584865 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin, rituximab, and risk-adapted chemotherapy.
Number of subjects: 30
Study 34039403 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated model of radiomics and clinical features
Number of subjects: 197
Study 34039403 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics model
Number of subjects: 197
Study 34039403 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical model
Number of subjects: 197
Study 32400186 — intervention group
Group type: EXPERIMENTAL
Intervention: Solar Conduction Dryer (SCD)
Number of subjects: 200
Study 32400186 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 200
Study 35950899 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib plus enzalutamide
Number of subjects: 1037
Study 35950899 — intervention group
Group type: COMPARATOR
Intervention: Enzalutamide plus placebo
Number of subjects: 1037
Study 34174191 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent HPV vaccine
Number of subjects: 0
Study 34174191 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 0
Study 35926984 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolytics (urokinase median dose 250,000 IU, alteplase median dose 20 mg)
Number of subjects: 2263
Study 35926984 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolytics
Number of subjects: 2263
Study 32191400 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA 300 mg twice daily
Number of subjects: 30
Study 32191400 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA 300 mg twice daily for 4 weeks followed by UDCA 300 mg twice daily and metformin 500 mg twice daily for 4 weeks
Number of subjects: 30
Study 32191400 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E 400 IU twice daily
Number of subjects: 30
Study 32442334 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy consisting of electrotherapy and biofeedback, 3 days a week for 3 months
Number of subjects: 60
Study 36205206 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (25,000 IU/d for 10 days)
Number of subjects: 182
Study 36205206 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (hydroxychloroquine)
Number of subjects: 182
Study 34472926 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective communication
Number of subjects: 117
Study 34472926 — intervention group
Group type: EXPERIMENTAL
Intervention: Externalizing behavior problems
Number of subjects: 117
Study 34472926 — intervention group
Group type: EXPERIMENTAL
Intervention: Observed parenting behaviors
Number of subjects: 117
Study 32546269 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course antibiotic therapy for 2 weeks
Number of subjects: 298
Study 32546269 — intervention group
Group type: COMPARATOR
Intervention: Conventional antibiotic therapy (4-6 weeks)
Number of subjects: 298
Study 35871815 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intramuscular glucocorticoid injection (120 mg) and a 1‐year course of oral methotrexate (up to 25 mg/week)
Number of subjects: 236
Study 35871815 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single injection and tablets for 1 year)
Number of subjects: 236
Study 35604466 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed rhythmic-melodic voice training (SIPARI)
Number of subjects: 20
Study 35604466 — intervention group
Group type: COMPARATOR
Intervention: Language therapy (control group)
Number of subjects: 20
Study 35984159 — intervention group
Group type: COMPARATOR
Intervention: Empirical concomitant therapy (CoT): rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg twice daily for 14 days
Number of subjects: 290
Study 35984159 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored therapy (TaT): rabeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg twice daily for 14 days for point mutation-negative patients; rabeprazole 20 mg twice daily, metronidazole 500 mg thrice daily, bismuth 120 mg, and tetracycline 500 mg 4 times daily for 14 days for point mutation-positive patients
Number of subjects: 290
Study 35984159 — intervention group
Group type: COMPARATOR
Intervention: Empirical concomitant therapy (CoT) in point mutation-positive patients
Number of subjects: 290
Study 35984159 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored therapy (TaT) in point mutation-positive patients
Number of subjects: 290
Study 35510343 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health promotion intervention (individual support to improve oral health)
Number of subjects: 263
Study 35510343 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 263
Study 33416422 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes
Number of subjects: 285
Study 33416422 — intervention group
Group type: COMPARATOR
Intervention: Type 2 diabetes
Number of subjects: 285
Study 35835650 — intervention group
Group type: EXPERIMENTAL
Intervention: HP-Guar nanoemulsion
Number of subjects: 20
Study 35835650 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 20
Study 34541982 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIME needle-free injection system
Number of subjects: 0
Study 34541982 — intervention group
Group type: COMPARATOR
Intervention: Standard needle and syringe
Number of subjects: 0
Study 35809825 — intervention group
Group type: EXPERIMENTAL
Intervention: Information on herd immunity (> 80% of the entire population must be vaccinated)
Number of subjects: 4288
Study 35809825 — intervention group
Group type: COMPARATOR
Intervention: Information on herd immunity (no information)
Number of subjects: 4288
Study 35809825 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine with 90% efficacy
Number of subjects: 4288
Study 35809825 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of adverse reactions to be 1 over 10 in 10,000
Number of subjects: 4288
Study 35809825 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge on herd immunity target
Number of subjects: 4288
Study 33684506 — intervention group
Group type: EXPERIMENTAL
Intervention: sucrose (80 g/day)
Number of subjects: 94
Study 33684506 — intervention group
Group type: EXPERIMENTAL
Intervention: fructose (80 g/day)
Number of subjects: 94
Study 33684506 — intervention group
Group type: EXPERIMENTAL
Intervention: glucose (80 g/day)
Number of subjects: 94
Study 33684506 — intervention group
Group type: COMPARATOR
Intervention: control group (SSB abstinence)
Number of subjects: 94
Study 35345950 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 76
Study 35345950 — intervention group
Group type: COMPARATOR
Intervention: Usual care (CG)
Number of subjects: 76
Study 33493346 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical malaria episodes
Number of subjects: 0
Study 32688041 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct decompression with wide posterior decompression and operative stabilization
Number of subjects: 46
Study 32688041 — intervention group
Group type: COMPARATOR
Intervention: Indirect decompression through ligamentotaxis
Number of subjects: 46
Study 32688041 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct decompression
Number of subjects: 46
Study 35457787 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote PA follow-up intervention after face-to-face program
Number of subjects: 30
Study 35457787 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI4 group (four behavior change coaching interviews)
Number of subjects: 30
Study 35457787 — intervention group
Group type: COMPARATOR
Intervention: BCI3 group (three behavior change coaching interviews)
Number of subjects: 30
Study 34059572 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality care (n=58)
Number of subjects: 116
Study 34059572 — intervention group
Group type: COMPARATOR
Intervention: Routine care (n=58)
Number of subjects: 116
Study 32353056 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (PA) measured using ActiGraph accelerometers
Number of subjects: 42
Study 32353056 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (PA) outdoors
Number of subjects: 42
Study 32353056 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult-managed time
Number of subjects: 42
Study 32353056 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (PA) at all intensity levels
Number of subjects: 42
Study 32353056 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (PA)
Number of subjects: 42
Study 35302945 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text messaging reminder
Number of subjects: 591
Study 35302945 — intervention group
Group type: COMPARATOR
Intervention: Email reminder
Number of subjects: 591
Study 35932209 — intervention group
Group type: EXPERIMENTAL
Intervention: T-piece Resuscitators (TPR)
Number of subjects: 0
Study 35932209 — intervention group
Group type: COMPARATOR
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 0
Study 33411915 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental Depression (PD)
Number of subjects: 200
Study 32080148 — intervention group
Group type: EXPERIMENTAL
Intervention: traditional treatment + intravenous infusion of edaravone 30 mg twice a day for 14 days
Number of subjects: 112
Study 34402135 — intervention group
Group type: COMPARATOR
Intervention: NOAC
Number of subjects: 144
Study 34402135 — intervention group
Group type: EXPERIMENTAL
Intervention: LAAC
Number of subjects: 144
Study 35255966 — intervention group
Group type: EXPERIMENTAL
Intervention: MenSC-derived secretome treatment (5 mL intravenous infusions for five days)
Number of subjects: 0
Study 35255966 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo, 5 mL intravenous infusions for five days)
Number of subjects: 0
Study 35255966 — intervention group
Group type: EXPERIMENTAL
Intervention: MenSC-derived secretome treatment
Number of subjects: 0
Study 33245674 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezo surgery
Number of subjects: 60
Study 33245674 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser surgery
Number of subjects: 60
Study 33245674 — intervention group
Group type: COMPARATOR
Intervention: Lindeman bur
Number of subjects: 60
Study 33245674 — intervention group
Group type: COMPARATOR
Intervention: Steel bur
Number of subjects: 60
Study 33245674 — intervention group
Group type: COMPARATOR
Intervention: Tungsten carbide bur
Number of subjects: 60
Study 33245674 — intervention group
Group type: COMPARATOR
Intervention: Diamond bur
Number of subjects: 60
Study 32138746 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin plus fenofibrate
Number of subjects: 853
Study 32138746 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin plus placebo
Number of subjects: 853
Study 35839158 — intervention group
Group type: EXPERIMENTAL
Intervention: Human amniotic membrane (HAM)
Number of subjects: 43
Study 35839158 — intervention group
Group type: COMPARATOR
Intervention: Bovine collagen
Number of subjects: 43
Study 35839158 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 43
Study 34304029 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted ASSIP intervention
Number of subjects: 34
Study 34304029 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual control
Number of subjects: 34
Study 34837169 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib test formulation (125 mg) under fasting condition
Number of subjects: 60
Study 34837169 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib test formulation (125 mg) under fed condition
Number of subjects: 60
Study 34837169 — intervention group
Group type: COMPARATOR
Intervention: Palbociclib reference formulation (125 mg) under fasting condition
Number of subjects: 60
Study 34837169 — intervention group
Group type: COMPARATOR
Intervention: Palbociclib reference formulation (125 mg) under fed condition
Number of subjects: 60
Study 32144056 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESPB)
Number of subjects: 60
Study 35866804 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosis SIS
Number of subjects: 186
Study 35866804 — intervention group
Group type: COMPARATOR
Intervention: Control SIS (commercial)
Number of subjects: 186
Study 34397802 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumboperitoneal shunt (LPS)
Number of subjects: 0
Study 34397802 — intervention group
Group type: COMPARATOR
Intervention: Ventriculoperitoneal shunt (VPS)
Number of subjects: 0
Study 34397802 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS and VPS
Number of subjects: 0
Study 32808029 — intervention group
Group type: EXPERIMENTAL
Intervention: L-cysteine (1200 mg)
Number of subjects: 19
Study 32808029 — intervention group
Group type: EXPERIMENTAL
Intervention: L-cysteine (600 mg)
Number of subjects: 19
Study 32808029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 35895764 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP-DEX (bupivacaine mixed with dexmedetomidine)
Number of subjects: 26
Study 35895764 — intervention group
Group type: EXPERIMENTAL
Intervention: BLS (bupivacaine liposomal suspension)
Number of subjects: 26
Study 35895764 — intervention group
Group type: COMPARATOR
Intervention: CTRL (no TAP block)
Number of subjects: 26
Study 35895764 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP-DEX and BLS
Number of subjects: 26
Study 33785271 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) or biliopancreatic diversion with duodenal switch (BPD/DS)
Number of subjects: 18
Study 32357152 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis group (n = 136)
Number of subjects: 349
Study 32357152 — intervention group
Group type: COMPARATOR
Intervention: Relaxation group (n = 134)
Number of subjects: 349
Study 32357152 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (n = 79)
Number of subjects: 349
Study 35468330 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral BPTB graft
Number of subjects: 88
Study 35468330 — intervention group
Group type: COMPARATOR
Intervention: Ipsilateral BPTB graft
Number of subjects: 88
Study 32789530 — intervention group
Group type: EXPERIMENTAL
Intervention: Bag-of-features (BOF) features with augmentation from contrast-enhanced MRI (CE-MRI)
Number of subjects: 56
Study 32789530 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomic analysis with pre-contrast MRI
Number of subjects: 56
Study 32789530 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis with CE-MRI
Number of subjects: 56
Study 34736546 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐AII (self-affirmation intervention)
Number of subjects: 175
Study 34736546 — intervention group
Group type: COMPARATOR
Intervention: N‐AII (non-affirming implementation intentions)
Number of subjects: 175
Study 34736546 — intervention group
Group type: COMPARATOR
Intervention: Control (mere goal intention condition)
Number of subjects: 175
Study 33318849 — intervention group
Group type: EXPERIMENTAL
Intervention: CBL combined with STEM education concept
Number of subjects: 0
Study 33318849 — intervention group
Group type: COMPARATOR
Intervention: Traditional education programme
Number of subjects: 0
Study 32493383 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Diagnostic Strategy (MODS) with D-dimer threshold raised to 1000 ng/ml if no items of the YEARS score are present.
Number of subjects: 0
Study 32493383 — intervention group
Group type: COMPARATOR
Intervention: Usual care with D-dimer threshold of 500 ng/ml for patients aged 50 years or younger and age × 10 for older patients.
Number of subjects: 0
Study 35293783 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 400 mg twice daily for 4 weeks
Number of subjects: 40
Study 35293783 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 125 mg twice daily for 4 weeks
Number of subjects: 40
Study 35293783 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 35308438 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual distraction (AVD)
Number of subjects: 60
Study 35308438 — intervention group
Group type: COMPARATOR
Intervention: Mute-video distraction (MVD)
Number of subjects: 60
Study 35308438 — intervention group
Group type: COMPARATOR
Intervention: Control technique
Number of subjects: 60
Study 32061387 — intervention group
Group type: EXPERIMENTAL
Intervention: Early measles vaccination (MV) at 4.5 + 9 months
Number of subjects: 3548
Study 32061387 — intervention group
Group type: COMPARATOR
Intervention: Control group (MV at 9 months)
Number of subjects: 3548
Study 32910863 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin antioxidant energy therapy
Number of subjects: 151
Study 32910863 — intervention group
Group type: COMPARATOR
Intervention: Standard conservative therapy
Number of subjects: 151
Study 34859519 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone monitoring and counseling (TMC; n = 59)
Number of subjects: 262
Study 34859519 — intervention group
Group type: EXPERIMENTAL
Intervention: Addiction comprehensive health enhancement support system (ACHESS; n = 68)
Number of subjects: 262
Study 34859519 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone monitoring and counseling + ACHESS (TMC + ACHESS; n = 70)
Number of subjects: 262
Study 34859519 — intervention group
Group type: COMPARATOR
Intervention: IOP only (TAU; n = 65)
Number of subjects: 262
Study 33789267 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic triamcinolone acetonide injections (up to 3 injections at 1-week intervals)
Number of subjects: 152
Study 33789267 — intervention group
Group type: COMPARATOR
Intervention: Intratympanic triamcinolone acetonide injections
Number of subjects: 152
Study 32646010 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention with a low-carbohydrate formula diet (INT)
Number of subjects: 141
Study 32646010 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention only (CON)
Number of subjects: 141
Study 35686351 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stimulation in-phase with slow oscillations
Number of subjects: 18
Study 35686351 — intervention group
Group type: COMPARATOR
Intervention: Sham condition without auditory stimuli
Number of subjects: 18
Study 34192419 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 2433334 (5–150 mg as oral solution or immediate-release tablets)
Number of subjects: 86
Study 34192419 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 2433334 (5 mg tablets) with a high-calorie breakfast
Number of subjects: 86
Study 34192419 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 2433334
Number of subjects: 86
Study 34192419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 36331590 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) and posterior nasal neurectomy (PNN)
Number of subjects: 46
Study 36331590 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 46
Study 34351722 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic-dose anticoagulation with heparin
Number of subjects: 1098
Study 34351722 — intervention group
Group type: COMPARATOR
Intervention: Usual-care thromboprophylaxis
Number of subjects: 1098
Study 32971450 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 IU/week)
Number of subjects: 92
Study 32971450 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate (500 μg/day)
Number of subjects: 92
Study 32971450 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vitamin D3 and chromium picolinate
Number of subjects: 92
Study 32971450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 35748058 — intervention group
Group type: EXPERIMENTAL
Intervention: YH4808 at 30, 50, 100, 200, 400, 600, and 800 mg (single oral dose)
Number of subjects: 0
Study 35748058 — intervention group
Group type: EXPERIMENTAL
Intervention: YH4808 at 100, 200, and 400 mg (multiple once-daily oral doses for 7 days)
Number of subjects: 0
Study 35748058 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole at 40 mg (active comparator)
Number of subjects: 0
Study 35748058 — intervention group
Group type: EXPERIMENTAL
Intervention: YH4808 (repeated doses)
Number of subjects: 0
Study 34182800 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A (institution's radial band deflation protocol)
Number of subjects: 100
Study 34182800 — intervention group
Group type: COMPARATOR
Intervention: Protocol B (Cohen and Alfonso's radial band deflation protocol)
Number of subjects: 100
Study 32212297 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with 4+ comorbidities
Number of subjects: 6945
Study 32212297 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher comorbidity burden
Number of subjects: 6945
Study 35380933 — intervention group
Group type: EXPERIMENTAL
Intervention: Trending norm messages
Number of subjects: 156
Study 35380933 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 156